SynAct Pharma Aps

Quick facts

Phase 2 pipeline

• AP1189 · Diabetes
  AP1189 is a glucagon receptor agonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• SynAct Pharma Aps portfolio CI brief
• SynAct Pharma Aps pipeline updates RSS